Table 3.
Reasons for discontinuing RPV or EFV
| RPV1 N (%) | EFV2 N (%) | |
|---|---|---|
| Median (IQR) duration of treatment at discontinuation (Months) | 18.2 (6.7–34.2) | 9.8 (3.4–23.1) |
| Treatment failure (virological, immunological, and/or clinical) | 29 (5.8) | 14 (9.5) |
| Toxicity | 73 (14.7) | 45 (30.4) |
| Predominantly from central nervous system (CNS) | 13 (2.6) | 33 (22.3) |
| Predominantly from kidneys | 20 (4.0) | 4 (2.7) |
| Liver | 6 (1.2) | 3 (2.0) |
| Hypersensitivity reaction (skin eruption etc.) | 3 (0.6) | 2 (1.4) |
| Predominantly from abdomen/GI tract | 13 (2.6) | 1 (0.7) |
| Abnormal fat redistribution | 2 (0.4) | 0 (0.0) |
| Cardiovascular disease | 2 (0.4) | 0 (0.0) |
| Dyslipidaemia | 0 (0.0) | 1 (0.7) |
| Other side effects–not specified | 14 (2.8) | 1 (0.7) |
| Other | ||
| Physician's decision, not specified | 167 (33.5) | 23 (15.5) |
| Participant's wish/decision, not specified | 38 (7.6) | 18 (12.2) |
| Availability of more effective treatment (not specifically failure or side effect related) | 15 (3.0) | 5 (3.4) |
| Structured Treatment Interruption (STI) | 3 (0.6) | 0 (0.0) |
| Enrolled in RCTs | 2 (0.4) | 0 (0.0) |
| Other causes, not specified | 91 (18.3) | 23 (15.5) |
| Unknown | 80 (16.1) | 20 (13.5) |
Reasons listed are those for stopping either RPV or EFV
1Denominator is the number of participants who have discontinued RPV (n = 498)
2Denominator is the number of participants who have discontinued EFV (n = 148)
Reasons for discontinuation can be found at https://hicdep.org/Wiki/v/9/pt/4/Table/36/FieldID/439